# Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function

> **NCT03562117** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** Gepotidacin

## Key facts

- **NCT ID:** NCT03562117
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-14
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03562117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03562117, "Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03562117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*